Indian pharmaceutical companies go on a buying spree to cut their risks by diversifying their portfolios and widening their revenue bases.
Home-grown drug companies are on an acquisition spree.They are also inking agreements with their global peers. These moves by domestic pharmaceutical companies are aimed at diversifying their product portfolios to consolidate their businesses across the globe.
Hyderabad-based Dr Reddy's Laboratories recently inked a pact with Teva Pharmaceutical and an affiliate of Allergan to buy a portfolio of eight abbreviated new drug applications (ANDAs) in the US for $350 million (around Rs 2,300 crore) in cash. On the other hand, Mumbai-head- quartered Cipla sealed a deal with Russia's National Immunobiological Company (NACIMBIO) recently to collaborate on HIV and Hepatitis C drugs, entailing an investment of 2.8 billion roubles (about Rs 289 crore). Besides, the Zydus Group also recently acquired two ANDAs from Teva for an undisclosed amount.
"As pharmaceutical companies globally look at consolidating in some way or the other, Indian pharmaceutical companies would do well to negotiate the new pharmaceutical landscape. It will also provide them the opportunity to actually benefit from spin-offs," opines Novartis India Vice- Chairman and MD Ranjit Shahani.
Shopping spree
Dr Reddy's is buying a portfolio that consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business. The portfolio being acquired is a mix of ANDAs filed and pending approval and an approved ANDA. The acquisition is comprised of complex generic products across diverse dosage forms, according to a statement of Dr Reddy's Laboratories.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Top Crisis
Short-term, consumer-centric measures have left the tomato, onion and potato farmers struggling to eke out a living.
Boon Or Bane?
With some adequate safeguards, the government's e-assessment scheme can be a win-win situation for both tax department and taxpayers.
Revisiting Development
Sustainable development is the way forward for India, which is in the midst of an economic downturn, ecological crises and stark human distress.
The Cabotage Debate
Relaxation of Cabotage rules has pitted foreign shipping lines against domestic shipping companies.
Catch-22
India finds itself in an unenviable position, as it weighs the pros and cons of joining RCEP.
Accept Mistakes Quickly
Anto Binish Kaspar is a firm believer in technology.
We Will Have 30 Franchisees By 2020
Naresh Sharma , CEO , Skora paints
The Revival Conundrum
Along with a patchwork of band-aids, a smart combination of monetary and fiscal measures can get the ailing economy back into the pink of health.
Mahatma Gandhi @150
The Mahatma firmly advocated that this world has enough for everyone's need but not greed. Gandhian economics, no wonder, cannot be more relevant today in times of erratic economic development, jobless growth and adverse climate changes.
Bitterness Lingers
A hike in subsidy does little to boost exports, thanks to a glut in the global market, and leaves sugar prices subdued in the domestic market.
